News | 01 August 2021
Ajanta Pharma Q1FY22 consolidated net profit up at Rs. 173.75 Cr
It posted net profit of Rs.147.76 crores for the period ended June 30, 2020.
It posted net profit of Rs.147.76 crores for the period ended June 30, 2020.
The company posted net profit of Rs.2.43 crores for the period ended June 30, 2020.
The group now has 320 approvals and has so far filed over 400 ANDAs
It posted net loss of Rs.(2429.81) crores for the period ended June 30, 2020.
The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.
The company posted net profit of Rs.16.18 crores for the period ended June 30, 2020.
The company posted net profit of Rs.124.45 crores for the period ended June 30, 2020.
The company posted net profit f Rs.85.45 crores for the period ended June 30, 2020.
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
The company reported total income Rs.18.57 crores during the period ended June 30, 2020.
The company posted net profit of Rs.321 crores for the period ended June 30, 2020.
The company posted net profit of Rs.594.6 crores for the period ended June 30, 2020.
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
The Cephalosporin Injectables plant has a total capacity of 26.4 million vials per year while Ethiopia is having a demand for 16 million vials
The company posted net loss of Rs.56.69 crores for the period ended June 30, 2020.
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
Subscribe To Our Newsletter & Stay Updated
